April Burke

The Scientist Date: January 6, 1997 THE SCIENTIST® The Newspaper for the Life Sciences Professional (609)-786-7207 For Fast Service I read THE SCIENTIST because it keeps me up to date on issues important to my business -- research funding trends, science policy, and oversight, advocacy, and more. I also learn more about research innovations from The Scientist and find that the publication influences my clients' opinions." April Burke, principal Lewis-Burke Associates Washington DC Was

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Scientist

Date: January 6, 1997

April Burke, principal
Lewis-Burke Associates
Washington DC

"That in itself isn't a bad thing," explains Burke. "But, inevitably, more scrutiny leads to new restrictions that require more oversight. We need to do a better job of convincing Congress that scientific institutions are responsible stewards of public money."

Burke has been working in the areas of health policy and research since starting her career in the mid-1970s drafting health legislation iin the Office of the Legislative Council of the U.S. Senate. After a stint at the Asssociation of American Universities in Washington D.C., Burke started her own lobbying firm, which represents only scientific institutions and organizations. "Our firm is half think tank and half advocacy organization," she asserts.

A reader of THE SCIENTIST, Burke says: "I read THE SCIENTIST because it keeps me up to date on issues important to my business -- research funding ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies